Belatacept denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for belatacept are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Issues a Not-FDA-Approved Denial for Belatacept

Belatacept holds FDA approval for a defined indication in adult kidney transplant recipients. A "not-FDA-approved" denial from UnitedHealthcare in this context almost always means one of two things: (1) the insurer contends the proposed use falls outside the FDA-approved indication — for example, a different transplant organ type or a pediatric patient — or (2) there is an administrative mismatch between the submitted diagnosis code and the approved indication. Either way, the denial is contestable.

## Why This Denial Is Appealable

If the use is within the FDA-approved indication, the denial rests on a factual error and should be corrected at internal appeal with proper documentation. If the use is off-label, federal law (and most state laws) still require plans to cover off-label uses that are supported by recognized compendia or accepted medical practice — particularly for transplant immunosuppression, an area where clinical evidence evolves faster than labeling cycles.

## Federal Appeal Framework

• ACA §2719 external review: Binding IRO review is available after exhausting internal appeals, typically within approximately four months of denial (confirm the exact deadline on your EOB). IROs regularly overturn not-FDA-approved denials when the evidence base is solid.
• ERISA §503: Entitles employer-plan members to the clinical criteria and compendia the plan relied on, allowing point-by-point rebuttal.
• Expedited review: Request if the patient's clinical condition cannot safely wait for the standard internal-appeal timeline.

## Concrete Appeal Steps

1. Obtain the denial letter and identify whether UHC is asserting the use is outside the approved indication or relying on a coding mismatch. 2. If a coding error: have the prescribing physician correct the diagnosis and resubmit with a corrected claim alongside the appeal. 3. If an off-label challenge: compile compendia support (e.g., references from recognized transplant medicine compendia) and literature. 4. Submit a written internal appeal with supporting documentation within the EOB deadline. 5. Escalate to external IRO review if the internal appeal is denied.

## Documentation to Gather

• FDA-approved prescribing label for belatacept: highlight the approved indication and confirm your patient's use is within or adjacent to it.
• Diagnosis confirmation: transplant records with organ type, transplant date, and current immunologic status.
• Prescriber attestation: letter stating the specific clinical basis for use, citing the FDA label and any relevant transplant society guideline, and explaining why the use is consistent with accepted medical practice.
• Compendia or guideline support for off-label uses: if applicable, cite the relevant guideline organization (e.g., the applicable KDIGO or AST guideline) without asserting specific statistics.

## Criteria-Mapping Structure

Obtain UnitedHealthcare's coverage policy for belatacept and its criteria for recognizing off-label uses. Map each criterion to a specific document in the chart or to a recognized compendia entry. This structured response transforms a vague coverage dispute into a concrete, answerable question for the IRO reviewer.